AUPH (Aurinia Pharmaceuticals) Margin of Safety % (DCF Dividends Based) : N/A (As of Dec. 11, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Aurinia Pharmaceuticals Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Aurinia Pharmaceuticals's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

Competitive Comparison of Aurinia Pharmaceuticals's Margin of Safety % (DCF Dividends Based)

For the Biotechnology subindustry, Aurinia Pharmaceuticals's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aurinia Pharmaceuticals's Margin of Safety % (DCF Dividends Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aurinia Pharmaceuticals's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Aurinia Pharmaceuticals's Margin of Safety % (DCF Dividends Based) falls into.

Aurinia Pharmaceuticals Margin of Safety % (DCF Dividends Based) Related Terms

Thank you for viewing the detailed overview of Aurinia Pharmaceuticals's Margin of Safety % (DCF Dividends Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Aurinia Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aurinia Pharmaceuticals Inc (NAS:AUPH) » Definitions » Margin of Safety % (DCF Dividends Based)

Comparable Companies

Traded in Other Exchanges

IKAP:Germany IKAP:Germany

Address

14315 118 Avenue, Suite 140, Edmonton, AB, CAN, T5L 4S6

Website

https://www.auriniapharma.com

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.

Executives

Karen L. Smith	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Jeffrey Allen Bailey	director	BIODELIVERY SCIENCES INTERNATIONAL, INC., 4131 PARKLAKE AVE., SUITE 225, RALEIGH NC 27612
Scott Michael Habig	officer: Chief Commercial Officer	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
R. Hector Mackay-dunn	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Jayne David R.w.	director	#1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Daniel Billen	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Jill Leversage	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Brinda Balakrishnan	director	#1203-4464 MARKHAM STREET, VICTORIA A1 V8Z7X8
Matthew Maxwell Donley	officer: Ex VP, Intern'l Operations	4520 EAST WEST HIGHWAY, 3RD FLOOR, BETHESDA MD 20814
Stephen P. Robertson	officer: EVP, General Counsel	#1203-4464 MARKHAM STREET, VICTORIA A1 BC V8Z7X8
Joseph M Miller	officer: Chief Financial Officer	C/O CERECOR INC., 400 EAST PRATT STREET, SUITE 606, BALTIMORE MD 21202
Peter Greenleaf	director, officer: Chief Executive Officer	ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Volker Knappertz	officer: EVP, Research and Development	SOVEREIGN HOUSE, VISION PARK, HISTON, CAMBRIDGE X0 CB249BZ
Robert T Foster	director	C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Joseph P Hagan	director	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037